MoonLake Immunotherapeutics reported on February 20, 2026, that it amended its loan agreement to secure an additional $400 million in future funding, including a $25 million draw, tied to clinical trial successes. The filing also noted a management change with Simon Sturge resigning from the Board effective February 28, 2026.